MHLW Orders Novartis To Improve After Side-Effect Report Delay
This article was originally published in PharmAsia News
Executive Summary
The MHLW in Japan has issued Novartis’s local subsidiary a business improvement order for not reporting serious side-effects caused by leukemia treatments within 30 days, as specified in the Pharmaceutical Affairs Law.